An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1

NCT03350451 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

PH1
Primary Hyperoxaluria
RNAi Therapeutic
siRNA
AGT

Interventions

DRUG: Lumasiran

Sponsor

Alnylam Pharmaceuticals